HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

XOMA

XOMA Royalty Corporation (NASDAQ)

Healthcare — Biotechnology

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

None 1 analysts
$40.17
+$40.17 (+100.00%)
Target: $39.00 (-2.9%)
Sign in to add XOMA to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$753.47M
P/E Ratio (TTM)27.15
Forward P/E19.92
EPS (TTM)$1.57
Dividend Yield-
Profit Margin69.63%
Revenue Growth-22.60%
ROE34.23%
Debt/Equity110.49
Recommendation None
Analyst Target$39.00
Analysts1
Indexes NASDAQ

Technical Indicators

RSI (14)77.3
Beta0.87
SMA 20-
SMA 40-
52-Week High$42.81
52-Week Low$22.29
50-Day Avg$41.53
200-Day Avg$33.48
Avg Volume325.0K
Volume-

Performance Analysis

NEUTRAL

XOMA presents a mixed picture with both positive and negative indicators.

+ Showing strength at 87% of its 52-week range.
- RSI at 77.3 indicates overbought conditions — a pullback may be due.
~ Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
- Revenue declined 22.6% year-over-year.
+ Healthy profit margin of 69.6%.
~ Wall Street consensus is "none" from 1 analysts.
- Average analyst target of $39.00 implies 2.9% downside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:38 UTC

Back to Screener Export Report